NO327328B1 - Farmasoytisk sammensetning som fast doseringsform samt fremgangsmate for fremstilling derav - Google Patents
Farmasoytisk sammensetning som fast doseringsform samt fremgangsmate for fremstilling derav Download PDFInfo
- Publication number
- NO327328B1 NO327328B1 NO20051896A NO20051896A NO327328B1 NO 327328 B1 NO327328 B1 NO 327328B1 NO 20051896 A NO20051896 A NO 20051896A NO 20051896 A NO20051896 A NO 20051896A NO 327328 B1 NO327328 B1 NO 327328B1
- Authority
- NO
- Norway
- Prior art keywords
- pharmaceutical composition
- range
- composition according
- dosage form
- solid dosage
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 55
- 238000000034 method Methods 0.000 title claims abstract description 37
- 239000007909 solid dosage form Substances 0.000 title claims abstract description 24
- 238000002360 preparation method Methods 0.000 title claims description 3
- 239000008187 granular material Substances 0.000 claims abstract description 53
- 239000000203 mixture Substances 0.000 claims abstract description 34
- 239000000314 lubricant Substances 0.000 claims abstract description 27
- 108010000437 Deamino Arginine Vasopressin Proteins 0.000 claims abstract description 26
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 22
- 239000003085 diluting agent Substances 0.000 claims abstract description 20
- 229960004281 desmopressin Drugs 0.000 claims abstract description 12
- NFLWUMRGJYTJIN-NXBWRCJVSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-NXBWRCJVSA-N 0.000 claims abstract description 12
- 239000004480 active ingredient Substances 0.000 claims abstract description 9
- 150000003839 salts Chemical class 0.000 claims abstract description 8
- 239000002245 particle Substances 0.000 claims description 44
- 238000007906 compression Methods 0.000 claims description 20
- 230000006835 compression Effects 0.000 claims description 20
- 229920002472 Starch Polymers 0.000 claims description 17
- 235000019698 starch Nutrition 0.000 claims description 17
- 150000002016 disaccharides Chemical class 0.000 claims description 16
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 16
- 239000008107 starch Substances 0.000 claims description 16
- 239000000126 substance Substances 0.000 claims description 14
- 238000009826 distribution Methods 0.000 claims description 12
- FIEYHAAMDAPVCH-UHFFFAOYSA-N 2-methyl-1h-quinazolin-4-one Chemical compound C1=CC=C2NC(C)=NC(=O)C2=C1 FIEYHAAMDAPVCH-UHFFFAOYSA-N 0.000 claims description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- 229960002845 desmopressin acetate Drugs 0.000 claims description 10
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 8
- 239000011230 binding agent Substances 0.000 claims description 8
- 239000008101 lactose Substances 0.000 claims description 8
- 235000019359 magnesium stearate Nutrition 0.000 claims description 8
- 229920001592 potato starch Polymers 0.000 claims description 7
- 235000021355 Stearic acid Nutrition 0.000 claims description 6
- 239000000654 additive Substances 0.000 claims description 6
- 230000015572 biosynthetic process Effects 0.000 claims description 6
- 150000002772 monosaccharides Chemical class 0.000 claims description 6
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 6
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 6
- 239000008117 stearic acid Substances 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 239000000080 wetting agent Substances 0.000 claims description 6
- 239000007884 disintegrant Substances 0.000 claims description 5
- 229920001542 oligosaccharide Polymers 0.000 claims description 5
- 150000002482 oligosaccharides Chemical class 0.000 claims description 5
- 239000003755 preservative agent Substances 0.000 claims description 5
- 230000000996 additive effect Effects 0.000 claims description 4
- 239000003086 colorant Substances 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 239000000796 flavoring agent Substances 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 3
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims description 3
- 239000008116 calcium stearate Substances 0.000 claims description 3
- 235000013539 calcium stearate Nutrition 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 3
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims description 3
- 235000013355 food flavoring agent Nutrition 0.000 claims description 3
- FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 claims description 3
- 229940046813 glyceryl palmitostearate Drugs 0.000 claims description 3
- 239000008172 hydrogenated vegetable oil Substances 0.000 claims description 3
- 239000000395 magnesium oxide Substances 0.000 claims description 3
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims description 3
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 230000002335 preservative effect Effects 0.000 claims description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 3
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims description 3
- 239000000454 talc Substances 0.000 claims description 3
- 229910052623 talc Inorganic materials 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 2
- 229940078456 calcium stearate Drugs 0.000 claims 2
- 229940057948 magnesium stearate Drugs 0.000 claims 2
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 claims 2
- 229940057977 zinc stearate Drugs 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 abstract description 6
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 8
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 8
- MLSVJHOYXJGGTR-IFHOVBQLSA-N acetic acid;(2s)-n-[(2r)-1-[(2-amino-2-oxoethyl)amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]-1-[(4r,7s,10s,13s,16s)-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,1 Chemical compound CC(O)=O.C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 MLSVJHOYXJGGTR-IFHOVBQLSA-N 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 238000005469 granulation Methods 0.000 description 4
- 230000003179 granulation Effects 0.000 description 4
- 229940028441 minirin Drugs 0.000 description 4
- 238000005056 compaction Methods 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000007916 tablet composition Substances 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000005580 one pot reaction Methods 0.000 description 2
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 159000000021 acetate salts Chemical class 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 201000010064 diabetes insipidus Diseases 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 238000003475 lamination Methods 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 206010029446 nocturia Diseases 0.000 description 1
- 208000005346 nocturnal enuresis Diseases 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- -1 sixtrate Chemical compound 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03016945A EP1500390B1 (en) | 2003-07-25 | 2003-07-25 | Pharmaceutical desmopressin composition as solid dosage form and method for manufacturing thereof |
| US10/626,857 US7022340B2 (en) | 2003-07-25 | 2003-07-25 | Pharmaceutical composition as solid dosage form and method for manufacturing thereof |
| PCT/EP2004/051538 WO2005011640A2 (en) | 2003-07-25 | 2004-07-19 | Pharmaceutical desmopressin composition as solid dosage form and method for manufacturing thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20051896L NO20051896L (no) | 2005-04-19 |
| NO327328B1 true NO327328B1 (no) | 2009-06-08 |
Family
ID=34117527
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20051896A NO327328B1 (no) | 2003-07-25 | 2005-04-19 | Farmasoytisk sammensetning som fast doseringsform samt fremgangsmate for fremstilling derav |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US7022340B2 (ja) |
| EP (1) | EP1500390B1 (ja) |
| JP (1) | JP4430673B2 (ja) |
| KR (1) | KR20050104331A (ja) |
| AT (1) | ATE301990T1 (ja) |
| AU (1) | AU2004260625B2 (ja) |
| BR (1) | BRPI0412905A (ja) |
| CA (1) | CA2490335C (ja) |
| DE (1) | DE60301351T2 (ja) |
| DK (1) | DK1500390T3 (ja) |
| ES (1) | ES2243840T3 (ja) |
| HK (1) | HK1072009A1 (ja) |
| IL (1) | IL187591A0 (ja) |
| MX (1) | MXPA06000903A (ja) |
| NO (1) | NO327328B1 (ja) |
| NZ (1) | NZ544104A (ja) |
| PL (1) | PL379704A1 (ja) |
| PT (1) | PT1500390E (ja) |
| RU (1) | RU2303439C2 (ja) |
| SI (1) | SI1500390T1 (ja) |
| TW (1) | TWI268782B (ja) |
| WO (1) | WO2005011640A2 (ja) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0210397D0 (en) | 2002-05-07 | 2002-06-12 | Ferring Bv | Pharmaceutical formulations |
| US7094545B2 (en) * | 2003-04-30 | 2006-08-22 | Ferring Bv | Pharmaceutical composition as solid dosage form and method for manufacturing thereof |
| CN1826099B (zh) * | 2003-07-25 | 2010-06-09 | 凡林有限公司 | 固体剂型药物组合物及其制造方法 |
| ATE324869T1 (de) * | 2003-11-13 | 2006-06-15 | Ferring Bv | Blisterverpackung und feste dosierungsform enthaltend desmopressin |
| US7018653B2 (en) * | 2003-12-29 | 2006-03-28 | Ferring B.V. | Method for preparing solid dosage form of desmopressin |
| CA2490601C (en) * | 2003-12-29 | 2006-05-02 | Ferring B.V. | Method for preparing solid dosage form of desmopressin |
| SE528446C2 (sv) * | 2006-03-02 | 2006-11-14 | Ferring Int Ct Sa | Farmaceutisk sammansättning innefattande desmopressin, kiseldioxid och stärkelse |
| ES2319054B1 (es) | 2007-08-06 | 2010-02-12 | Gp Pharm S.A. | Composicion farmaceutica oral de desmopresina. |
| KR101522747B1 (ko) | 2007-08-06 | 2015-05-26 | 알레간 인코포레이티드 | 데스모프레신 약물 전달을 위한 방법 및 장치 |
| EP2249813A1 (en) * | 2008-03-11 | 2010-11-17 | Mallinckrodt Inc. | Use of magnesium stearate dihydrate for lubrication of solid pharmaceutical compositions |
| US20100286045A1 (en) | 2008-05-21 | 2010-11-11 | Bjarke Mirner Klein | Methods comprising desmopressin |
| PT2712622T (pt) * | 2008-05-21 | 2016-10-13 | Ferring Bv | Desmopressina orodispersível para aumentar o período inicial de sono tranquilo |
| US11963995B2 (en) | 2008-05-21 | 2024-04-23 | Ferring B.V. | Methods comprising desmopressin |
| US20110178229A1 (en) * | 2008-09-30 | 2011-07-21 | Hirofumi Goda | Fiber-reinforced resin composition and molded body thereof |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8306367L (sv) * | 1983-11-18 | 1985-05-19 | Ferring Ab | Antidiuretiskt verkande farmaceutiskt preparat |
| US4675188A (en) * | 1985-08-02 | 1987-06-23 | Stauffer Chemical Company | Granular anhydrous dicalcium phosphate compositions suitable for direct compression tableting |
| US4820627A (en) * | 1986-03-24 | 1989-04-11 | Em Diagnostic Systems, Inc. | Method of preparing particles suitable for tabletting into diagnostic reagents |
| US5482931A (en) | 1993-06-29 | 1996-01-09 | Ferring Ab | Stabilized pharmaceutical peptide compositions |
| WO1995018602A1 (en) | 1994-01-11 | 1995-07-13 | Alkermes Controlled Therapeutics, Inc. | ORAL DOSAGE FORM OF DESMOPRESSIN (dDAVP) |
| SE9400918L (sv) | 1994-03-18 | 1995-09-19 | Anne Fjellstad Paulsen | Stabiliserad komposition för oral administrering av peptider |
| US5849322A (en) | 1995-10-23 | 1998-12-15 | Theratech, Inc. | Compositions and methods for buccal delivery of pharmaceutical agents |
| GB9526495D0 (en) | 1995-12-23 | 1996-02-28 | Knoll Ag | Therapeutic agents |
| DE19602757A1 (de) * | 1996-01-26 | 1997-07-31 | Boehringer Mannheim Gmbh | Feste Instant-Release-Darreichungsformen und Verfahren zu ihrer Herstellung |
| WO2000009423A1 (es) | 1998-08-11 | 2000-02-24 | Jaime Marti Sala | Silo para almacenamiento de cuerpos huecos ligeros |
| AT409081B (de) | 2000-02-16 | 2002-05-27 | Gebro Pharma Gmbh | Stabile, nasal, oral oder sublingual anwendbare pharmazeutische zubereitung |
| GB0009469D0 (en) * | 2000-04-17 | 2000-06-07 | Vectura Ltd | Improvements in or relating to formalities for use in inhaler devices |
| WO2001078696A2 (en) | 2000-04-17 | 2001-10-25 | Vectura Limited | Formulations for use in inhaler devices |
| PE20011227A1 (es) | 2000-04-17 | 2002-01-07 | Chiesi Farma Spa | Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros |
| GB0010709D0 (en) | 2000-05-03 | 2000-06-28 | Vectura Ltd | Powders for use a in dry powder inhaler |
| ES2632461T3 (es) | 2000-06-27 | 2017-09-13 | Vectura Limited | Formulaciones para su uso en dispositivos inhaladores |
| KR20040047915A (ko) | 2001-10-15 | 2004-06-05 | 룀 게엠베하 운트 콤파니 카게 | 활성제로서 펩타이드 또는 단백질을 함유하는 생약 형태를제조하기 위한 공중합체의 용도 |
| NZ535861A (en) | 2002-05-07 | 2006-11-30 | Ferring Bv | Desmopressin acetate in an orodispersible dosage form that disintegrates in the mouth within 10 seconds |
| ATE291419T1 (de) * | 2003-04-30 | 2005-04-15 | Ferring Bv | Feste dosierungsform mit desmopressin |
| US7094545B2 (en) * | 2003-04-30 | 2006-08-22 | Ferring Bv | Pharmaceutical composition as solid dosage form and method for manufacturing thereof |
-
2003
- 2003-07-25 ES ES03016945T patent/ES2243840T3/es not_active Expired - Lifetime
- 2003-07-25 SI SI200330100T patent/SI1500390T1/sl unknown
- 2003-07-25 DE DE60301351T patent/DE60301351T2/de not_active Expired - Lifetime
- 2003-07-25 PT PT03016945T patent/PT1500390E/pt unknown
- 2003-07-25 AT AT03016945T patent/ATE301990T1/de active
- 2003-07-25 US US10/626,857 patent/US7022340B2/en not_active Expired - Fee Related
- 2003-07-25 DK DK03016945T patent/DK1500390T3/da active
- 2003-07-25 EP EP03016945A patent/EP1500390B1/en not_active Revoked
-
2004
- 2004-07-19 CA CA002490335A patent/CA2490335C/en not_active Expired - Fee Related
- 2004-07-19 JP JP2006520833A patent/JP4430673B2/ja not_active Expired - Fee Related
- 2004-07-19 NZ NZ544104A patent/NZ544104A/en not_active IP Right Cessation
- 2004-07-19 AU AU2004260625A patent/AU2004260625B2/en not_active Ceased
- 2004-07-19 BR BRPI0412905-9A patent/BRPI0412905A/pt not_active Application Discontinuation
- 2004-07-19 KR KR1020057006309A patent/KR20050104331A/ko not_active Application Discontinuation
- 2004-07-19 MX MXPA06000903A patent/MXPA06000903A/es active IP Right Grant
- 2004-07-19 WO PCT/EP2004/051538 patent/WO2005011640A2/en active Application Filing
- 2004-07-19 RU RU2005141230/15A patent/RU2303439C2/ru not_active IP Right Cessation
- 2004-07-19 PL PL379704A patent/PL379704A1/pl not_active Application Discontinuation
- 2004-07-23 TW TW093122090A patent/TWI268782B/zh not_active IP Right Cessation
-
2005
- 2005-04-19 NO NO20051896A patent/NO327328B1/no not_active IP Right Cessation
- 2005-06-13 HK HK05104919A patent/HK1072009A1/xx not_active IP Right Cessation
-
2007
- 2007-11-22 IL IL187591A patent/IL187591A0/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005011640A3 (en) | 2005-03-24 |
| CA2490335A1 (en) | 2005-01-25 |
| JP4430673B2 (ja) | 2010-03-10 |
| PL379704A1 (pl) | 2006-11-13 |
| EP1500390B1 (en) | 2005-08-17 |
| SI1500390T1 (sl) | 2006-02-28 |
| AU2004260625B2 (en) | 2007-12-06 |
| WO2005011640A2 (en) | 2005-02-10 |
| TWI268782B (en) | 2006-12-21 |
| MXPA06000903A (es) | 2006-05-04 |
| BRPI0412905A (pt) | 2006-09-26 |
| TW200509995A (en) | 2005-03-16 |
| DK1500390T3 (da) | 2005-09-19 |
| US20050019392A1 (en) | 2005-01-27 |
| KR20050104331A (ko) | 2005-11-02 |
| RU2303439C2 (ru) | 2007-07-27 |
| DE60301351T2 (de) | 2006-01-19 |
| US7022340B2 (en) | 2006-04-04 |
| IL187591A0 (en) | 2008-03-20 |
| PT1500390E (pt) | 2005-10-31 |
| JP2007517762A (ja) | 2007-07-05 |
| NO20051896L (no) | 2005-04-19 |
| CA2490335C (en) | 2006-01-31 |
| ES2243840T3 (es) | 2005-12-01 |
| NZ544104A (en) | 2008-06-30 |
| RU2005141230A (ru) | 2006-07-10 |
| HK1072009A1 (en) | 2005-08-12 |
| DE60301351D1 (de) | 2005-09-22 |
| EP1500390A1 (en) | 2005-01-26 |
| ATE301990T1 (de) | 2005-09-15 |
| AU2004260625A1 (en) | 2005-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO327328B1 (no) | Farmasoytisk sammensetning som fast doseringsform samt fremgangsmate for fremstilling derav | |
| US20110033535A1 (en) | Pharmaceutical composition as solid dosage form and method for manufacturing thereof | |
| US9713594B2 (en) | Methods for making pharmaceutical solid dosage forms of spray-dried dispersions | |
| US20060252696A1 (en) | Pharmaceutical composition as solid dosage form and method for manufacturing thereof | |
| CA2486833C (en) | Solid dosage form comprising desmopressin and method for manufacturing thereof | |
| RU2715680C2 (ru) | Таблетки ибупрофена натрия и способы изготовления фармацевтических композиций, включающих ибупрофен натрия | |
| US20070154543A1 (en) | Solid preparation for oral use | |
| AU2015264861B2 (en) | Sodium ibuprofen tablets and methods of manufacturing pharmaceutical compositions including sodium ibuprofen | |
| CN115998694A (zh) | 一种含有布瑞哌唑的口腔崩解片及其制备方法 | |
| CA2511353A1 (en) | Solid dosage form comprising desmopressin and method for manufacturing thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |